Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

IMPORTANCE: Guidelines currently recommend ticagrelor over clopidogrel for patients with acute coronary syndrome (ACS) based on randomized clinical trial data in which ticagrelor reduced major adverse coronary events (MACE) vs clopidogrel but increased bleeding and dyspnea. OBJECTIVE: To compare the...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA Intern Med
Päätekijät: Turgeon, Ricky D., Koshman, Sheri L., Youngson, Erik, Har, Bryan, Wilton, Stephen B., James, Matthew T., Graham, Michelle M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Medical Association 2020
Aiheet:
Original Investigation
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6990835/
https://ncbi.nlm.nih.gov/pubmed/31930361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamainternmed.2019.6447
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia